Matthew Ros
CIK 1673802 · Chief Operating Officer · last filed 2026-06-11
Matthew Ros is a Chief Operating Officer who has filed 44 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing, for COGT, was dated Jun 11, 2026. Across all open-market trades the lifetime net is −$3.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $432.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
EPZM price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
400 TECHNOLOGY SQUARE
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| COGT | Director | — | $29.52 | — | $0 | 19 | 2026-06-11 |
| VSTM | Chief Operating Officer | 50,000 | $8.65 | $432.5K | $0 | 1 | 2025-04-03 |
| Epizyme, Inc. (EPZM) Delisted | See Remarks | 111,313 | $1.47 | $163.6K | -$3.75M | 17 | 2021-08-18 |
| Cogent Biosciences, Inc. (UMRX) Delisted | Director | — | — | — | $0 | 7 | 2020-10-02 |
Recent Filings
44 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-11 | COGT | Grant (A) | — | $0 | EDGAR |
| 2025-06-05 | COGT | Grant (A) | — | $0 | EDGAR |
| 2025-04-03 | VSTM | Grant (A) | +50,000 | $0 | EDGAR |
| 2024-06-13 | COGT | Grant (A) | — | $0 | EDGAR |
| 2024-01-04 | COGT | Grant (A) | — | $0 | EDGAR |
| 2023-10-03 | COGT | Grant (A) | — | $0 | EDGAR |
| 2023-07-05 | COGT | Grant (A) | — | $0 | EDGAR |
| 2023-06-08 | COGT | Grant (A) | — | $0 | EDGAR |
| 2023-04-04 | COGT | Grant (A) | — | $0 | EDGAR |
| 2023-01-04 | COGT | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.